Effect of chronic administration of low dose rapamycin on development and immunity in young rats

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Lu, Zhenya ^a   Liu, Furong ^b   Chen, Linglin ^b   Zhang, Huadan ^b   Ding, Yuemin ^b   Liu, Jianxiang ^b   Wong, Michael ^c   Zeng, Ling Hui ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY CITY COLLEGE   (China)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; S6 KINASE; TUMOR NECROSIS FACTOR ALPHA; DOUBLECORTIN PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN DERIVATIVE; MICROTUBULE ASSOCIATED PROTEIN; MTOR PROTEIN, RAT; NEUROPEPTIDE; TARGET OF RAPAMYCIN KINASE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; BRAIN LEVEL; CELL MATURATION; CELLULAR IMMUNITY; COGNITIVE DEFECT; CONTROLLED STUDY; DENTATE NUCLEUS; DRUG ACTIVITY; FEMALE; HIPPOCAMPUS; IMMUNITY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MAZE TEST; MORRIS WATER MAZE TEST; NEOCORTEX; NONHUMAN; OPEN FIELD TEST; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SYNAPTOGENESIS; TISSUE DISTRIBUTION; AGE; ANIMAL; ANTAGONISTS AND INHIBITORS; ANXIETY; BODY WEIGHT; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; ORGAN SIZE; PATHOLOGY; PHOSPHORYLATION; SPLEEN; SPRAGUE DAWLEY RAT; THYMUS;

AGE FACTORS; ANIMALS; ANXIETY; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HIPPOCAMPUS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKINS; MALE; MAZE LEARNING; MICROTUBULE-ASSOCIATED PROTEINS; NEOCORTEX; NEUROPEPTIDES; ORGAN SIZE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RIBOSOMAL PROTEIN S6 KINASES; SIROLIMUS; SPLEEN; THYMUS GLAND; TOR SERINE-THREONINE KINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84941992295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135256     Document Type: Article

References (41)

1. Kobau R, Zahran H, Thurman DJ, Zack MM, Henry TR, Schachter SC, et al. (2008) Epilepsy surveillance among adults-19 States, Behavioral Risk Factor Surveillance System, 2005. MMWR Surveill Summ 57:1-20.
2. Wiebe S, Hesdorffer DC (2007) Epilepsy: being ill in more ways than one. Epilepsy Curr 7:145-148. PMID: 18049719
3. Klehm J, Thome-Souza S, Sanchez Fernandez I, Bergin AM, Bolton J, Harini C, et al. (2014) Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. Pediatr Neurol 51:60-66. doi: 10.1016/j.pediatrneurol.2014.01.025 PMID: 24830765
4. Maitre NL, Smolinsky C, Slaughter JC, Stark AR (2013) Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. J Perinatol 33:841-846. doi: 10.1038/jp. 2013.116 PMID: 24051577
5. Zeng LH, Xu L, Gutmann DH, Wong M (2008) Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 63:444-453. doi: 10.1002/ana.21331 PMID: 18389497
6. Sunnen CN, Brewster AL, Lugo JN, Vanegas F, Turcios E, Mukhi S, et al. (2011) Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice. Epilepsia 52:2065-2075. doi: 10.1111/j.1528-1167.2011.03280.x PMID: 21973019
7. Zeng LH, Rensing NR, Wong M (2009) The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 29:6964-6972. doi: 10.1523/JNEUROSCI.0066-09.2009 PMID: 19474323
8. Buckmaster PS, Ingram EA, Wen X (2009) Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J Neurosci 29:8259-8269. doi: 10.1523/JNEUROSCI.4179-08.2009 PMID: 19553465
9. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149:274-293. doi: 10.1016/j.cell.2012.03.017 PMID: 22500797
10. Wong M (2013) A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials. Expert Rev Neurother 13:657-669. doi: 10.1586/ern. 13.48 PMID: 23739003
11. Talos DM, Sun H, Zhou X, Fitzgerald EC, Jackson MC, Klein PM, et al. (2012) The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS One 7:e35885. doi: 10.1371/journal.pone.0035885 PMID: 22567115
12. Raman L, Kong X, Kernie SG (2013) Pharmacological inhibition of the mTOR pathway impairs hippocampal development in mice. Neurosci Lett 541:9-14. doi: 10.1016/j.neulet.2013.01.045 PMID: 23395832
13. Chen LL, Feng HF, Mao XX, Ye Q, Zeng LH (2013) One hour of pilocarpine-induced status epilepticus is sufficient to develop chronic epilepsy in mice, and is associated with mossy fiber sprouting but not neuronal death. Neurosci Bull 29:295-302. doi: 10.1007/s12264-013-1310-6 PMID: 23471864
14. Bannerman DM, Niewoehner B, Lyon L, Romberg C, Schmitt WB, Taylor A, et al. (2008) NMDA receptor subunit NR2A is required for rapidly acquired spatial working memory but not incremental spatial reference memory. J Neurosci 28:3623-3630. doi: 10.1523/JNEUROSCI.3639-07.2008 PMID: 18385321
15. Chen L, Hu L, Dong JY, Ye Q, Hua N, Wong M, et al. (2012) Rapamycin has paradoxical effects on S6 phosphorylation in rats with and without seizures. Epilepsia 53:2026-2033. doi: 10.1111/epi.12013 PMID: 23145776
16. Kawatsu S, Oda K, Saiki Y, Tabata Y, Tabayashi K (2007) External application of rapamycin-eluting film at anastomotic sites inhibits neointimal hyperplasia in a canine model. Ann Thorac Surg 84:560-567; discussion 567. PMID: 17643635
17. Chan CC, Martin DF, Xu D, Roberge FG (1995) Side effects of rapamycin in the rat. J Ocul Pharmacol Ther 11:177-181. PMID: 8564638
18. Rangel EB (2014) Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drugdrug interactions. Expert Opin Drug Metab Toxicol 10:1585-1605. doi: 10.1517/17425255.2014. 964205 PMID: 25255841
19. Aboujaoude W, Milgrom ML, Govani MV (2004) Lymphedema associated with sirolimus in renal transplant recipients. Transplantation 77:1094-1096. PMID: 15087777
20. De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, et al. (2009) Conversion from acalcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicentertrial. LiverTranspl 15:1262-1269. doi: 10.1002/lt.21827 PMID: 19790150
21. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125-132. doi: 10.1016/S0140-6736 (12) 61134-9 PMID: 23158522
22. Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczynski D, Kmiec T, et al. (2013) Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol 17:479-485. doi: 10.1016/j.ejpn. 2013.03.002 PMID: 23567018
23. Cambiaghi M, Cursi M, Magri L, Castoldi V, Comi G, Comi G, et al. (2013) Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex. Neuropharmacology 67:1-7. doi: 10.1016/j.neuropharm.2012.11.003 PMID: 23159330
24. Way SW, Rozas NS, Wu HC, McKenna J 3rd, Reith RM, Hashmi SS, et al. (2012) The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex. Hum Mol Genet 21:3226-3236. doi: 10.1093/hmg/dds156 PMID: 22532572
25. Tsai PT, Greene-Colozzi E, Goto J, Anderl S, Kwiatkowski DJ, Sahin M. (2013) Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57BL/6 mice. Behav Genet 3:51-59.
26. Tang SJ, Reis G, Kang H, Gingras AC, Sonenberg N, Schuman EM. (2002) A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A 99:467-472. PMID: 11756682
27. Jaworski J, Spangler S, Seeburg DP, Hoogenraad CC, Sheng M (2005) Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci 25:11300-11312. PMID: 16339025
28. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, et al. (2008) Reversal of learning deficits in aTsc2+/-mouse model of tuberous sclerosis. Nat Med 14:843-848. doi: 10.1038/nm1788 PMID: 18568033
29. Brewster AL, Lugo JN, Patil VV, Lee WL, Qian Y, Vaneqas F, et al. (2013) Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage. PLoS One 8:e57808. doi: 10.1371/journal. pone.0057808 PMID: 23536771
30. Gangarossa G, Ceolin L, Paucard A, Lerner-Natoli M, Perroy J, Fagni L, et al. (2014) Repeated stimulation of dopamine D1-like receptor and hyperactivation of mTOR signaling lead to generalized seizures, altered dentate gyrus plasticity, and memory deficits. Hippocampus 24:1466-1481 doi: 10.1002/hipo. 22327 PMID: 25044816
31. Neff F, Flores-Dominguez D, Ryan DP, Horsch M, Schroder S, Adler T, et al. (2013) Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest 123:3272-3291. doi: 10.1172/JCI67674 PMID: 23863708
32. Blagosklonny MV (2013) Rapamycin extends life- and health span because it slows aging. Aging (Albany NY) 5:592-598.
33. Stallone G, Infante B, Grandaliano G, Gesualdo L (2009) Management of side effects of sirolimus therapy. Transplantation 87:S23-26. doi: 10.1097/TP.0b013e3181a05b7a PMID: 19384183
34. Hailer NP (2008) Immunosuppression after traumatic or ischemic CNS damage: it is neuroprotective and illuminates the role of microglial cells. Prog Neurobiol 84:211-233. doi: 10.1016/j.pneurobio.2007. 12.001 PMID: 18262323
35. Nichols LA, Adang LA, Kedes DH (2011) Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug. PLoSOne 6:e14535. doi: 10.1371/journal. pone.0014535 PMID: 21264294
36. Jhunjhunwala S, Balmert SC, Raimondi G, Dons E, Nichols EE, Thomson AW, et al. (2012) Controlled release formulations of IL-2, TGF-beta1 and rapamycin for the induction of regulatory T cells. J Control Release 159:78-84. doi: 10.1016/j.jconrel.2012.01.013 PMID: 22285546
37. Taylor-Fishwick DA, Kahan M, Hiestand P, Ritter MA, Foxwell BM (1993) Evidence that rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use. Transplantation 56:368-374. PMID: 7689258
38. Houde VP, Brule S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y, et al. (2010) Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59(6):1338-1348. doi: 10.2337/db09-1324 PMID: 20299475
39. Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, et al. (2014) Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 13:468-4772. doi: 10.1111/acel.12194 PMID: 24341993
40. Lin AL, Zheng W, Halloran JJ, Burbank RR, Hussong SA, Hart MJ, et al. (2013) Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer/'s disease. J Cereb Blood FlowMetab 33:1412-1421. doi: 10. 1038/jcbfm.2013.82 PMID: 23801246
41. Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, et al. (2012) Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell 11:326-335. doi: 10.1111/j.1474-9726.2011.00791.x PMID: 22212527